Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System

Next Previous
X
Search
Trial Profile

A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 04 May 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aspirin (Primary) ; Clopidogrel (Primary) ; Everolimus (Primary) ; Prasugrel (Primary) ; Ticagrelor (Primary)
  • Indications Coronary artery restenosis; Coronary stent thrombosis; Myocardial infarction; Thrombosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms EVOLVE Short DAPT
  • Sponsors Boston Scientific Corporation

    • Most Recent Events

    • 06 Mar 2023 Results of post-hoc analysis comparing bleeding and ischemic risk stratified into less than 4% and greater and equal to 4% bleeding risk groups, presented at the 72nd Annual Scientific Session of the American College of Cardiology together with the World Heart Federation.
    • 30 Mar 2020 Primary endpoint has been met. (Stent Thrombosis (ST))
    • 30 Mar 2020 Primary endpoint has been met. (Death or Myocardial Infarction (MI))

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top